Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

PURPOSE: The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Disis, Mary L., Wallace, Danelle R., Gooley, Theodore A., Dang, Yushe, Slota, Meredith, Lu, Hailing, Coveler, Andrew L., Childs, Jennifer S., Higgins, Doreen M., Fintak, Patricia A., dela Rosa, Corazon, Tietje, Kathleen, Link, John, Waisman, James, Salazar, Lupe G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2009
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754913/
https://ncbi.nlm.nih.gov/pubmed/19720923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6789
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia